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BRIEF REPORTS
Introduction
Hepcidin, synthesized mainly by hepatocytes and secreted
in plasma,1,2 plays a role in the control of iron metabolism3 by
interacting with ferroportin,4 the major iron exporter
expressed especially on macrophages and on basolateral
membranes of enterocytes. Hepcidin induces  degradation of
ferroportin and thus iron sequestration within these cells.4,5
Therefore, hepcidin may modulate plasma iron concentration
and transferrin saturation. 
The homozygous p.Cys282Tyr mutation of HFE gene is the
most frequent etiology of genetic hemochromatosis (GH)6
linked to an inaccurate low level of hepcidin regarding iron
status.7,8 The molecular mechanisms linking the p.Cys282Tyr
mutation and low hepcidin levels are not fully characterized.
Mutations in other genes, including transferrin receptor 2
(TFR2), hemojuvelin (HJV) and ferroportin (FPN),9,10 as well as
in coding and non-coding regions of hepcidin (HAMP),11-13 are
known to  induce phenotypic presentations similar to HFE
related GH. HFE related GH is a disease with incomplete pen-
etrance.6 This suggests that modifier genes modulate the
expressivity of HFE hemochromatosis. Mutations in hepcidin
(HAMP), TFR2 or HJV genes have been demonstrated to favor
the development of iron overload in p.Cys282Tyr heterozy-
gote patients14 and to increase iron burden in p.Cys282Tyr
HFE homozygotes.15,16
In HFE-GH it can be hypothesized that every genetic factor
lowering hepcidin gene expression could lead to a more
severe phenotype. Therefore, we searched for mutations in
iron metabolism regulatory genes in one patient with
homozygous p.Cys282Tyr mutation presenting  severe iron
overload. We identified a heterozygous mutation located
within the recently reported BMP-RE17 which could influence
hepcidin gene expression. In this report, we demonstrate that
the nc.-153 C>T hepcidin promoter mutation decreases its
transcriptional activity thus underlining the potential impact
of mutation in BMP-RE of hepcidin promoter on iron metab-
olism in humans. 
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Low levels of hepcidin are responsible for the development
of iron overload in p.Cys282Tyr HFE related hemochro-
matosis. Every genetic factor lowering the hepcidin gene
expression could contribute to a more severe phenotype in
HFE hemochromatosis. Based on this hypothesis, we iden-
tified a heterozygous nc.-153 C>T mutation in the hep-
cidin gene promoter sequence in a patient homozygous for
the p.Cys282Tyr HFE mutation who presented massive
iron overload, resisting to well conducted iron depletive
treatment.  Our results demonstrate that the nc.-153 C>T
mutation, located within a BMP-RE (Bone Morphogenetic
Protein-Responsive Element): i) decreases the transcription-
al activity of the hepcidin promoter, ii) alters its IL-6
(Interleukin-6) total responsiveness, and iii) prevents the
binding of the SMAD protein complex (1/5/8 and 4) to the
BPM-RE.  In conclusion, our results suggest that a mutation
in the BMP-RE of hepcidin promoter may impact on
human iron metabolism.
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Design and Methods
Patient and genetic studies
In 1994, the diagnosis of genetic hemochromatosis
was established in a 37 year old man with massive
hepatic iron overload (450 µmoL of iron/g dry liver
weight, n<36) involving mainly hepatocytes and associ-
ated to liver fibrosis stage 2-3 in Metavir classification.18
Iron depletive treatment based on weekly 400 mL phle-
botomies was initiated. In 1997, the patient was
demonstrated to be homozygous for the p.Cys282Tyr
mutation. In 2004 (47 years), 468 venesections had been
performed, corresponding to the removal of 85g of iron.
However, the patient was always exhibiting abnormal
iron parameters with 40 µmol/L for serum iron, 100%
for transferrin saturation, and 2,066 µg/L for serum fer-
ritin. In addition, hepatic iron concentration remained
very high (close to 300 µmol/g dry liver weight) at MRI.
Serum hepcidin level quantified by Elisa19 was low (24
ng/L; 29<N< 254 for men) despite major iron overload
with a decoupling between serum hepcidin and ferritin
values compared to the correlation between both
parameters reported by Ganz et al.19 Clinical iron burden
consisted of asthenia, icthyosis, melanodermia, gonal-
gia, osteoporosis, and hypogonadism. There were no
heart symptoms and serum glucose was normal.
Prothrombin time was normal (90%). Serum transami-
nases and GGT activities were slightly increased (1,5-
2N). Complete sequencing of the coding sequence of
the HFE, HJV, TFR2, FPN and HAMP (including its pro-
moter) genes was performed, as part of the diagnostic
procedure, after having obtained a written informed
consent from the patient. Unfortunately, the realization
of a family study did not prove possible. 
Sequencing of these genes was performed in one hun-
dred subjects recruited from a health appraisal center
with normal iron metabolism as judged on serum iron
parameters and hemoglobin levels. These subjects had
given their informed written consent for the study of
iron metabolism genes after approval of the protocol by
the local ethical committee (98/35-197). 
Cell culture 
Human hepatoma HepG2 cells were grown in
Minimum Essential Medium α (invitrogen) supplement-
ed with 10% fetal bovine serum (invitrogen), 100 UI/mL
penicillin, 100 mg/mL streptomycin and 2 mM L-gluta-
mine.
Plasmid constructions
The -1024 bp from the translation start site of the
human hepcidin promoter were amplified from HuH7
genomic DNA and  subcloned into pGL4.17 (Promega)
to generate -1024/BMP-RE wt Hep/Luc plasmid con-
struct. The internal mutations in the BMP responsive
element or in the STAT3 DNA binding site were made
using -1024 Hep/Luc as template and the internal fol-
lowing primers: GCCTTTTCGGTGCCACCACC;
antisense GGTGGTGGCACCGAAAAGGC for BMP-
RE or CACCTTCTTGGCCGTGAGAC, antisense
GTCTCACGGCCAAGAAGGTG for STAT3 binding
site. The nucleotide mutations are underlined. The iden-
tity of the constructs was confirmed by DNA sequenc-
ing. 
Transfection, luciferase assay
Cells were transfected, using transfectine (Bio-Rad)
with 100 ng of pGL4-hepcidin promoter vector with a
normalization plasmid (pRL-TK, Promega). After 48 h
Luciferase activities were measured in cell lysates using
the Dual-Luciferase-Reporter assay system (Promega)
and a Centro LB 960 luminometer (Berthold
Technologies). For treatments, either 10 ng/mL of
human BMP9 or 20ng/ml of human BMP4 or 20 ng/mL
IL-6 (R&D systems) were added to the cells for 48 h. 
Electrophoretic mobility shift assay
HepG2 cells were incubated with either 10 ng/mL of
human BMP9 or 20 ng/mL of human BMP4  for one
hour. Then crude nuclear extracts were prepared as
described.20 For gel retardation assays, nuclear extracts
(10 µg) were preincubated with 250 ng of poly(dI-
dC).poly(dI-dC), used as non-specific competitor DNA,
in a binding buffer (10 mM Tris-HCl pH 7.5, 50mM
NaCl, 1mM DTT, 1 mM EDTA, 5% glycerol) for 10 min
on ice. This mixture was then added to the 32P-end-
labeled probe either with or without specific competitor
oligonucleotides, and the incubation was carried out for
a further 30 min at room temperature. Gel shift assay
with purified polyclonal rabbit IgG anti-SMAD4 or anti-
SMAD1/5/8 (Santa Cruz) or non-relevant antibody
were performed under the same conditions except that
the antibodies were preincubated with nuclear extracts
for one hour on ice.  Complexes were resolved by elec-
trophoresis on prerun Tris-Glycine 5% native polyacry-
lamide gels. The following chemically synthesized dou-
ble-stranded oligonucleotides were used as probes and
as specific competitors (nucleotide mutation is under-
lined): BMPRE-wt GCCTTTTCGGCGCCACCACC,
BMPRE-mut GCCTTTTCGGTGCCACCACC.
Results and Discussion
The heterozygous nc -153 C>T was found in hepcidin
promoter
In genetic hemochromatosis, iron loading results from
abnormally low levels of hepcidin linked to mutations
in the hepcidin gene itself or in genes involved in hep-
cidin expression control, such as the HFE, HJV and TfR2
genes.9,10 This prompted us to search for additional
mutations in iron regulatory genes in a p.Cys282YTyr
homozygous patient presenting a massive iron over-
load.  The sequencing of the HFE gene confirmed the
homozygous p.CysC282Tyr mutation and excluded
another mutation. In addition, sequencing of HJV, TFR2
and FPN genes were normal. Finally, sequencing of the
hepcidin gene led to the identification of a punctual
mutation in position -153 from the translational start
site. This mutation was localized within the BMP-RE as
recently proposed,17 and was found neither in the web
databases nor in 200 chromosomes issued from 100
healthy volunteers.
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The heterozygous nc.-153 C>T mutation decreases
hepcidin promoter transcriptional activity
As described previously,17 the BMP-RE controls human
hepcidin promoter transcriptional activity under steady
state-condition. In order to assess the effect of the het-
erozygous nc.-153 C>T mutation on basal hepcidin gene
expression, plasmid constructs containing the -1024 bp
of the human hepcidin promoter with the wild type or
the mutated BMP-RE inserted among the luciferase gene
(-1024/BMP-RE wt Hep/Luc and -1024/BMP-RE mut
Hep/Luc) were transfected in HepG2 cells. Luciferase
activity from the -1024/BMP-RE mut Hep/Luc construct
was about 2.4 fold reduced compared to the luciferase
activity from the plasmid construct containing the wild
type BMP-RE (Figure 1, lanes 1-2), demonstrating that
this mutation decreased hepcidin transcriptional activity
in basal condition. As this BMP-RE mediates the induc-
tion of hepcidin gene expression in response to BMP,17
HepG2 cells were transfected with the -1024/BMP-RE
wt or mutated Hep/Luc plasmid constructs and were
treated with either BMP9 or BMP4 in order to determine
if the mutation impaired or not the response to these
BMPs.21 As expected, for -1024/BMP-RE wt Hep/Luc
construct, the BMP9 treatment increased luciferase activ-
ity by about 2.7 fold and BMP4 treatment by 1.8 fold
(Figure 1, lanes 1,4,6). By contrast, with the -1024/BMP-
RE mut Hep/Luc after BMP9 or BMP4 treatment, there
was no change observed for luciferase activities com-
pared to the basal condition (Figure 1, lanes 2,5,7). These
results demonstrate that the heterozygous nc.-153 C>T
mutation affects the basal hepcidin gene expression and
impairs its BMP4/9 response. 
Hepcidin gene responsiveness to IL-6 has been record-
ed decreasing when the BMP-RE or STAT3 binding sites
are mutated17 or in SMAD4–/– mice.22 Accordingly, we
found (Figure 1, lanes 8-9), by comparing the impact of
IL-6 on wild type and mutated promoter, that the
nc.153C>T was critical for IL-6 total responsiveness.
However, the mutation did not affect the ability to
respond in terms of fold induction, by comparing the
ratio between basal and IL-6 stimulated mutated con-
struct (Figure1 lanes 2,9) to the ratio between basal and
IL-6 stimulated wild type construct. (Figure 1, lanes 1,8).
To test the severity of the mutation we performed a
dose dependent assessment of the BMP4 effect (Figure
2). Whereas we found a dose dependent induction of
Luciferase activity from the -1024/BMP-RE wt, no
response was observed for the -1024/BMP-RE mut con-
struct, thus demonstrating the critical impact of the
mutation on the BMP related signaling. Taken together,
these results demonstrate that the nc.-153 C>T mutation
affects the basal hepcidin gene expression and impairs
its response to BMP4/9 and the IL-6 total responsive-
ness.
The heterozygous nc.-153 C>T mutation impairs the
binding of SMAD1/5/8/4 to the BMP-RE
The BMP-RE DNA region is a potential binding site
Figure 1. The heterozygous -153C/T
mutation decreases hepcidin promoter
transcription activity. HepG2 cells were
transfected with the -1024/BMP-RE wt or
-1024/BMP-RE mut Hep/Luc constructs
and were treated with  BMP9 (lanes 4,5),
BMP4 (lanes 6,7), IL-6 (lanes 8,9,10) or
not (lanes 1-2) for 48 h. Luciferase activ-
ity values represent Firefly/Renilla
Luciferase activity ratios relative to that
obtained with the -1024/BMP-RE wt
Hep/Luc plasmid construct, which was
arbitrarily set at 100%. Data represent
means of at least three independent
experiments (± SEM). *p<0.001 com-
pared to the -1024/BMP-RE wt Hep/Luc
construct and #p<0.001 compared to the
-1024/BMP-RE mut determined by 1-way
ANOVA and the Student-Newman-Keuls
comparisons test.
Figure 2. The -1024 BMPRE-wt Hep/Luc
but not the mutated constructs
responds in a dose-dependent manner
to BMP4. HepG2 cells were transfected
with the -1024 BMPRE wt or mutated
and were treated with increasing amount
of BMP4.
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for SMAD1/5/8 transcription factors, which are phos-
phorylated upon BMP binding to their receptors and
migrate to the nucleus associated to SMAD4, to activate
transcription of target genes.23 In order to determine if
the heterozygous nc.-153 C>T mutation impaired the
formation of a nucleoprotein complex of SMAD1/5/8
with the BMP-RE, an EMSA was performed using
nuclear extracts from HepG2 cells treated or not with
BMP4 or BMP9 and probes containing the wild type or
mutated BMP-RE. A complex was observed using the
probe containing the wild type BMP-RE (Figure 3A,
lanes 1,3,5; complex I). This complex I is present to a
lower extent in nuclear extracts obtained from basal
condition compared to those from BMP stimulated
cells. The complex I formation was inhibited by using a
probe which contained the mutated BMP-RE (Figure
3A, lanes 2,4,6). The specificity of formation of this
complex with the probe containing the wild type BMP-
RE was demonstrated using unlabeled oligonucleotides
containing wild type or mutated BMP-RE in excess.
Complex I binding was competed with the wild type
BMP-RE used as cold competitor (Figure 3B, lanes 1-4)
whereas competitor with the mutated BMP-RE had no
effect (Figure 3B, lanes 5-8), thus demonstrating its bind-
ing specificity. The lower band was not affected by the
wt competitor, demonstrating its unspecificity. 
To identify the protein content of complex I, HepG2
nuclear extracts were incubated with antibodies against
a non-relevant protein as control, SMAD4 or
SMAD1/5/8. Supershifts were observed with anti-
SMAD4 antibody and anti-SMAD1/5/8 antibody
specifically blocked the nucleoprotein complex I forma-
tion, thus inducing its disappearance. These results sug-
gest that in HepG2 cells, a nucleoprotein complex con-
taining the SMAD1/5/8/4 proteins is observed with the
wild type BMP-RE DNA binding site and that this
nucleoprotein complex formation is abrogated by the
nc.-153 C>T mutation. Thus, the impairment of
SMAD1/5/8/4 binding to the nc.-153 C>T mutated
BMP-RE could reduce hepcidin gene expression. 
Taken together, our data supports the deleterious
impact of the nc.-153 C>T hepcidin promoter mutation.
The iron depletive treatment (85g of iron subtracted,
including 18g potentially absorbed iron during the
whole venesection period, according to Olsson et al.24
was only partially successful as compared with what
can be expected in classical HFE hemochromatosis as
well as in juvelin hemochromatosis related to either
hepcidin or hemojuvelin gene mutations. These data
suggest that: i) the nc.-153 C>T mutation may have an
additive effect to the homozygous p.Cys282Tyr muta-
tion, which remains to be characterized and, ii) that the
addition of an iron chelator treatment could be relevant
both to potentiate iron elimination and to limit venesec-
tion-related iron absorption.
Our overall results suggest that mutations in BMP-RE
of hepcidin promoter may alter iron homeostasis, con-
tributing to the increase in the iron burden in HFE relat-
ed hemochromatosis.
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Figure 3. The -153C/T mutation impairs the binding of
SMAD1/5/8/4 to the BMP responsive element. (A) EMSA was per-
formed using HepG2 cell nuclear extracts treated or not with
either BMP4 or BMP9, which were incubated with radiolabeled
probes containing the BMP-RE wt or mutated. The presence of a
nucleoprotein complex (complex I) was found with the BMP-RE wt
probe and not with the mutated. (B) Binding specificity of complex
I was ascertained by EMSA using HepG2 cell nuclear extracts
treated or not with either BMP4 or BMP9, which were incubated
with the radiolabeled probe containing the BMP-RE wt and 12.5,
25 or 50 fold excess of cold competitor oligonucleotides contain-
ing the BMP-RE wt or mutated. The second arrowhead corre-
sponds to an unspecific complex. (C) Protein content of complex I
was analyzed by EMSA using HepG2 cell nuclear extracts treated
or not with either BMP4 or BMP9, which were incubated with a
non-relevant, SMAD4 or SMAD1/5/8  antibody.
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